𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Second primary tumors in patients with cutaneous malignant melanoma

✍ Scribed by Smita Bhatia; Lilian Estrada-Batres; Tamara Maryon; Monica Bogue; David Chu


Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
81 KB
Volume
86
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Several studies report coexistent or subsequent primary tumors (SPT) among patients with malignant melanoma (MM), with the rate of incidence ranging from 1.5-20% depending on the sample size and the length and completeness of follow-up.

METHODS.

The authors followed a cohort of patients with cutaneous MM who were diagnosed and treated at the City of Hope National Medical Center to determine the incidence rate of SPT and associated risk factors. Five hundred eighty-five patients (median age at diagnosis, 43 years) were diagnosed and treated for MM between 1952 and 1996 and followed for a median of 6.5 years (range, 0.0 -37.0 years). Ninety-six percent of the cohort had been treated by surgery alone.

RESULTS.

Thirty-seven patients developed an SPT. These included skin cancers (n Ο­ 23), carcinoma of the urinary bladder, breast carcinoma, and lymphoma (n Ο­ 3 each), lung carcinoma and prostate carcinoma (n Ο­ 2 each), and cervical carcinoma (n Ο­ 1). The estimated cumulative rate of incidence after MM was 5% at 5 years for any SPT, 3.7% for a second skin cancer, and 1.1% for a second solid tumor. Overall, the current cohort of MM patients was found to be at an increased risk for developing a subsequent melanoma (standardized incidence ratio [SIR], 4.5; 95% confidence interval [95% CI], 1.2-10.0) when compared with the general population. Older men (age ΟΎ 50 years at the time of diagnosis of MM) were at an increased risk of developing subsequent bladder carcinoma (SIR, 6.4; 95% CI, 1.2-15.7).

CONCLUSIONS.

Patients diagnosed with MM are at an increased risk of developing subsequent MM and bladder carcinoma. Issues to be addressed in future studies include interactions between environmental exposures and genetic susceptibility and the identification of individuals at increased risk.


πŸ“œ SIMILAR VOLUMES


Cutaneous melanoma in patients with sarc
✍ Carola Berking; Mary S. Brady πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 105 KB πŸ‘ 1 views

melanoma and sarcoma when they reviewed their experience with other malignancies occurring in patients with a diagnosis of sarcoma. 1 Medical Student, Ludwig-Maximilians-Univer- ## METHODS. The authors identified 48 patients with both melanoma and bone or sity, Munich, Germany. soft tissue sarco

The risk of subsequent primary carcinoma
✍ Maryjean Schenk; Richard K. Severson; Karen S. Pawlish πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 69 KB πŸ‘ 1 views

## Background: Carcinoma of the pancreas is the fifth leading cancer in the u.s. and has the poorest survival rate of the major malignancies. recent studies have reported an increased risk of carcinoma of the pancreas in malignant melanoma-prone kindreds and have suggested a link between malignant

Sentinel node biopsy in patients with cu
✍ Ferdinando Cafiero; Alberto Peressini; Marco Gipponi; Maria Luisa Rainero; Giuse πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 28 KB

The role of elective lymph node dissection (ELND) for treatment of cutaneous melanoma is still debated. Initially, lymphatic mapping technique was performed by an intradermic injection of vital blue dye; subsequently, it was improved by the use of radioguided surgery (RGS). Preliminary experience wi

Estrogen receptors in patients with mali
✍ Edward T. Creagan; James N. Ingle; John E. Woods; Douglas J. Pritchard; Nai-Sian πŸ“‚ Article πŸ“… 1980 πŸ› John Wiley and Sons 🌐 English βš– 213 KB πŸ‘ 1 views